

Anti- PEG Antibody (Clone 26A04)

Rat Monoclonal Antibody Catalog # ABV10781

Specification

Anti- PEG Antibody (Clone 26A04) - Product Information

Application WB, E
Reactivity All Species

Host Rat

Clonality Monoclonal Isotype IgM

Anti- PEG Antibody (Clone 26A04) - Additional Information

Positive Control 3 PEG Conjugates (20 kDa, 5 kDa, 10 kDa) Other Names

Target/Specificity

Polyethylene Glycol

PEG

Antibody Form

Liquid

AppearanceColorless liquid

Formulation

1 mg/ml in TBS, pH 9.0

Handling

The antibody solution should be gently mixed before use.

Reconstitution & Storage

-20 °C

Background Descriptions

Precautions

Anti- PEG Antibody (Clone 26A04) is for research use only and not for use in diagnostic or therapeutic procedures.

Anti- PEG Antibody (Clone 26A04) - Protein Information

Anti- PEG Antibody (Clone 26A04) - Protocols





Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Anti- PEG Antibody (Clone 26A04) - Images

Anti- PEG Antibody (Clone 26A04) - Background

Polyethylene Glycol (PEG) is a polymer of ethylene oxide available in size variants from 400 Da to 40 kDa. It is nonionic, nontoxic, biocompatible, strong, and hydrophilic and has a large exclusion volume in aqueous solution. PEG has a number of industrial and biomedical applications. The modification of a biopharmaceutical with PEG increases its hydrodynamic radius, reduces immunogenicity and proteolytic cleavage. In particular, therapeutic proteins are conj μ gated with PEG to slow down their clearance from circulation and improve bioavailability. PEG antibodies can be a vital tool for propelling therapeutics to market by serving as a positive control anti-dr μ g antibody, measuring clearance of a dr μ g, or simply as a QA release confirming PEGylation.